incidence and risk of secondary malignancy in patients with cll
Published 1 year ago • 65 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
3:34
the incidence and clinical correlates of non-immune cytopenia at cll diagnosis
-
3:41
the cll treatment infection model: identifying patients with cll at high risk of infections
-
1:48
patient risk stratification in cll and selection of treatment approaches
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
2:55
a model including cd49d expression to predict outcomes in patients with cll treated with ibrutinib
-
2:10
a study investigating the incidence of treatment-emergent autoimmune cytopenias in cll
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
2:01
the evolution of bcl2 inhibition in cll
-
5:41
infectious complications of cll: prevention and treatment
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:41
btk and plcg2 mutations in cll patients taking ibrutinib
-
2:54
the definition of high-risk cll
-
1:04
defining high-risk cll: known and emerging mutations
-
1:52
evaluating surrogacy endpoints in cll clinical trials
-
2:20
adverse prognostic features & treatment response in cll
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
2:24
prevalence of btk and plcγ2 mutations in cll relapsing under ibrutinib
-
0:36
the use of ai for analyzing genetic and molecular data in cll
-
2:19
long-term management of cll for improved outcomes
-
1:33
key factors affecting treatment decision making in cll
-
1:13
monitoring patients with cll on ibrutinib-based therapies
-
2:36
treatment approaches to cll with high-risk molecular features